Clinical Data AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis BioSpaceUCB's Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie's Skyrizi in a Phase 3 head-to-head study of psoriatic arthritis.Immunology & InflammationRead full story pharminent May 20, 2026 (Last updated: May 21, 2026) BioSpace UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study of psoriatic arthritis. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: GHO, CBC merge to create largest healthcare investment firmNext: Parabilis follows hefty Regeneron deal with IPO push Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
